Cambridge Trust’s Abeona Therapeutics ABEO Stock Holding History

Cambridge Trust’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-13	Closed	-$55	–	688
2023 Q3	$55	Hold	13	–	–	﹤0.01%	705
2023 Q2	$52	Hold	13	–	–	﹤0.01%	691
2023 Q1	$37	Hold	13	–	–	﹤0.01%	759
2022 Q4	$0	Sell	13 -65,060	-100%	-$243K	﹤0.01%	794
2022 Q3	$12K	Buy	65,073 +62,456	+2,387%	+$258K	﹤0.01%	616
2022 Q2	$14K	Hold	2,617	–	–	﹤0.01%	636
2022 Q1	$21K	Hold	2,617	–	–	﹤0.01%	659
2021 Q4	$22K	Hold	2,617	–	–	﹤0.01%	663
2021 Q3	$73K	Hold	2,617	–	–	﹤0.01%	271
2021 Q2	$102K	Hold	2,617	–	–	﹤0.01%	273
2021 Q1	$123K	Hold	2,617	–	–	0.01%	265
2020 Q4	$103K	Hold	2,617	–	–	﹤0.01%	229
2020 Q3	$67K	Hold	2,617	–	–	﹤0.01%	234
2020 Q2	$191K	Hold	2,617	–	–	0.01%	235
2020 Q1	$137K	Hold	2,617	–	–	0.01%	222
2019 Q4	$214K	Hold	2,617	–	–	0.01%	259
2019 Q3	$148K	Hold	2,617	–	–	0.01%	255
2019 Q2	$313K	Hold	2,617	–	–	0.02%	207
2019 Q1	$481K	Hold	2,617	–	–	0.03%	167
2018 Q4	$467K	Hold	2,617	–	–	0.03%	169
2018 Q3	$837K	Hold	2,617	–	–	0.05%	141
2018 Q2	$1.05M	Hold	2,617	–	–	0.07%	129
2018 Q1	$939K	Hold	2,617	–	–	0.06%	138
2017 Q4	$1.04M	Hold	2,617	–	–	0.07%	131
2017 Q3	$1.11M	Hold	2,617	–	–	0.07%	122
2017 Q2	$419K	Hold	2,617	–	–	0.03%	186
2017 Q1	$327K	Hold	2,617	–	–	0.02%	224
2016 Q4	$317K	Hold	2,617	–	–	0.02%	217
2016 Q3	$392K	Hold	2,617	–	–	0.03%	196
2016 Q2	$154K	Hold	2,617	–	–	0.01%	249
2016 Q1	$167K	Hold	2,617	–	–	0.01%	225
2015 Q4	$220K	Hold	2,617	–	–	0.02%	204
2015 Q3	$265K	Hold	2,617	–	–	0.02%	183
2015 Q2	$331K	Buy	+2,617	New	+$393K	0.03%	165

Other funds holding ABEO

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WSL

Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Cambridge Trust's ABEO Position: Q4 2023 in Review

Cambridge Trust sold out of Abeona Therapeutics (ABEO) in Q4 2023, closing a stake of 13 shares — an estimated $55 sold.

Cambridge Trust first reported a position in ABEO in Q2 2015 and held it in 34 quarters. The position peaked at $1.11M in Q3 2017. 48 funds tracked by Wall St. Rank hold ABEO as of Q4 2023.

Cambridge Trust reported no remaining Abeona Therapeutics position as of Q4 2023 after selling out during the quarter.
Cambridge Trust sold 13 Abeona Therapeutics shares in Q4 2023, an estimated $55.
Cambridge Trust first reported a position in Abeona Therapeutics in Q2 2015 and held it in 34 quarters.
Cambridge Trust's Abeona Therapeutics position peaked at $1.11M in Q3 2017.
48 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q4 2023.

Based on Cambridge Trust's 13F filing for Q4 2023, filed 31 Jan 2024.